Acrux raises $1.6 million via Share Placement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company received binding commitments exceeding the amount raised, indicating strong investor interest in its ongoing projects. Proceeds will support the development of female testosterone and a co-development agreement with an international partner. Additionally, participants in the placement will be offered attaching options, subject to shareholder approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux strategy focuses on Female Testosterone for low libido
- Acrux receives $0.55m advance on FY26 R&D Tax Incentive
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Acrux
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Notification regarding unquoted securities - ACR
- Application for quotation of securities - ACR
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux